MX2014005331A - Compuestos de heteroaril piridona y aza-piridona. - Google Patents

Compuestos de heteroaril piridona y aza-piridona.

Info

Publication number
MX2014005331A
MX2014005331A MX2014005331A MX2014005331A MX2014005331A MX 2014005331 A MX2014005331 A MX 2014005331A MX 2014005331 A MX2014005331 A MX 2014005331A MX 2014005331 A MX2014005331 A MX 2014005331A MX 2014005331 A MX2014005331 A MX 2014005331A
Authority
MX
Mexico
Prior art keywords
pyridone
compounds
aza
heteroaryl
inhibitors
Prior art date
Application number
MX2014005331A
Other languages
English (en)
Spanish (es)
Inventor
Binqing Wei
Daniel Fred Ortwine
James John Crawford
Wendy B Young
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014005331A publication Critical patent/MX2014005331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2014005331A 2011-11-03 2012-11-02 Compuestos de heteroaril piridona y aza-piridona. MX2014005331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555393P 2011-11-03 2011-11-03
PCT/US2012/063194 WO2013067274A1 (en) 2011-11-03 2012-11-02 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Publications (1)

Publication Number Publication Date
MX2014005331A true MX2014005331A (es) 2014-05-28

Family

ID=47146779

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014005331A MX2014005331A (es) 2011-11-03 2012-11-02 Compuestos de heteroaril piridona y aza-piridona.
MX2015003514A MX361807B (es) 2011-11-03 2012-11-02 Compuestos de heteroaril piridona y aza-piridona.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015003514A MX361807B (es) 2011-11-03 2012-11-02 Compuestos de heteroaril piridona y aza-piridona.

Country Status (34)

Country Link
US (11) US8716274B2 (OSRAM)
EP (5) EP3521288B1 (OSRAM)
JP (5) JP5976827B2 (OSRAM)
KR (2) KR101659193B1 (OSRAM)
CN (2) CN107011348B (OSRAM)
AR (2) AR088641A1 (OSRAM)
AU (5) AU2012332365B2 (OSRAM)
CA (1) CA2853975C (OSRAM)
CL (1) CL2014001103A1 (OSRAM)
CO (1) CO6950472A2 (OSRAM)
CR (1) CR20140194A (OSRAM)
CY (1) CY1117097T1 (OSRAM)
DK (2) DK2773638T3 (OSRAM)
EA (1) EA023263B1 (OSRAM)
ES (3) ES2555168T3 (OSRAM)
HR (2) HRP20151442T1 (OSRAM)
HU (2) HUE044959T2 (OSRAM)
IL (1) IL232060A (OSRAM)
IN (1) IN2014CN03250A (OSRAM)
LT (1) LT3002284T (OSRAM)
MA (1) MA35819B1 (OSRAM)
MX (2) MX2014005331A (OSRAM)
PE (1) PE20141586A1 (OSRAM)
PH (1) PH12014500936A1 (OSRAM)
PL (3) PL3521288T3 (OSRAM)
PT (2) PT2773638E (OSRAM)
RS (2) RS54505B1 (OSRAM)
SG (1) SG11201401992YA (OSRAM)
SI (2) SI3002284T1 (OSRAM)
TR (1) TR201909849T4 (OSRAM)
TW (4) TW202124384A (OSRAM)
UA (1) UA111756C2 (OSRAM)
WO (1) WO2013067274A1 (OSRAM)
ZA (1) ZA201804727B (OSRAM)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX2014005289A (es) * 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de piperazina alquilados.
RU2016101548A (ru) 2013-07-03 2017-08-08 Ф. Хоффманн-Ля Рош Аг Соединения амидов гетероарилпиридона и азапиридона
JP2016535764A (ja) * 2013-10-04 2016-11-17 ビヨンド オンコロジー ファーマシューティカル エルエルシー ブルトンのチロシンキナーゼの阻害剤
CN105793251B (zh) * 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
WO2016050921A1 (en) 2014-10-02 2016-04-07 F. Hoffmann-La Roche Ag Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
EP3212645B1 (en) 2014-10-27 2018-11-28 F.Hoffmann-La Roche Ag Process for making tricyclic lactam compounds
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
AR105875A1 (es) 2015-09-02 2017-11-15 GLAXOSMITHKLINE INTELLECTUAL PROPERTY (Nº 2) LTD Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio
WO2017070708A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
WO2017140821A1 (en) * 2016-02-19 2017-08-24 Novartis Ag Tetracyclic pyridone compounds as antivirals
KR102451106B1 (ko) * 2016-02-29 2022-10-06 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물
CN108473510B (zh) * 2016-04-28 2021-10-29 豪夫迈·罗氏有限公司 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
JP2020511462A (ja) 2016-12-03 2020-04-16 ジュノー セラピューティクス インコーポレイテッド キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
KR102375771B1 (ko) * 2016-12-15 2022-03-17 에프. 호프만-라 로슈 아게 Btk 억제제 제조 방법
DK3559000T3 (da) 2016-12-22 2022-06-07 Betta Pharmaceuticals Co Ltd Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf
TW201836642A (zh) * 2017-03-24 2018-10-16 美商建南德克公司 治療自體免疫及發炎疾病的方法
CN107445981B (zh) * 2017-08-25 2018-06-22 牡丹江医学院 一种用于防治宫颈炎的活性化合物
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
US11440912B2 (en) 2017-10-27 2022-09-13 Fresenius Kabi Oncology Ltd Process for the preparation of ribociclib and its salts
US11100492B2 (en) 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
WO2019177937A1 (en) 2018-03-12 2019-09-19 Arbutus Biopharma, Inc. Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
EP3789040A4 (en) 2018-04-27 2022-03-09 ONO Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
US20220362357A1 (en) 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
AU2019360928B2 (en) 2018-10-15 2023-11-09 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US12083114B2 (en) 2018-12-19 2024-09-10 Disarm Therapeutics, Inc. Inhibitors of SARM1 in combination with neuro-protective agents
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
TW202033523A (zh) * 2019-01-17 2020-09-16 美商愛彼特生物製藥股份有限公司 經取代的多環羧酸、其類似物及使用其之方法
CA3125236A1 (en) 2019-01-22 2020-07-30 F. Hoffmann-La Roche Ag Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
JP2022522153A (ja) * 2019-02-25 2022-04-14 グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド Ｂｔｋおよびその変異体の阻害剤
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
WO2020210508A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
CN114206855B (zh) 2019-05-17 2024-11-26 紐力克斯治疗公司 用于Cbl-b抑制的氰基环丁基类化合物及其用途
BR112021026241A2 (pt) 2019-06-26 2022-06-07 Nurix Therapeutics Inc Compostos de benzil-triazol substituído para inibição de cbl-b e outros usos dos mesmos
US20220363689A1 (en) 2019-10-05 2022-11-17 Newave Pharmaceutical Inc. Inhibitor of btk and mutants thereof
WO2021091575A1 (en) * 2019-11-08 2021-05-14 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
JP2023504147A (ja) 2019-12-04 2023-02-01 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介したｂｔｋの分解のための二官能性化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
PH12022552177A1 (en) * 2020-02-20 2023-12-11 Hutchison Medipharma Ltd Heteroaryl heterocyclic compounds and uses thereof
MX2022010513A (es) 2020-02-28 2022-09-21 Genentech Inc Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
MX2022012310A (es) 2020-04-03 2022-10-27 Genentech Inc Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
WO2021254483A1 (zh) * 2020-06-18 2021-12-23 上海华汇拓医药科技有限公司 布鲁顿酪氨酸激酶抑制剂及其制备方法
JP7771161B2 (ja) * 2020-08-04 2025-11-17 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のためのピリジノン化合物
CN116406259A (zh) * 2020-08-14 2023-07-07 广州麓鹏制药有限公司 包含btk及其突变体的抑制剂的剂型组合物
KR20230051227A (ko) 2020-08-14 2023-04-17 노파르티스 아게 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도
JP2023542040A (ja) * 2020-09-21 2023-10-04 ハチソン メディファルマ リミテッド ヘテロアリール複素環化合物及びその使用
US20230382900A1 (en) 2020-10-30 2023-11-30 Newave Pharmaceutical Inc. Inhibitors of btk
AU2021401056A1 (en) 2020-12-20 2023-08-03 Guangzhou Lupeng Pharmaceutical Company Ltd. Btk degrader
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
JP2024514836A (ja) 2021-04-08 2024-04-03 ニューリックス セラピューティクス，インコーポレイテッド Ｃｂｌ－ｂ阻害化合物との組み合わせ療法
ES3012969T3 (en) 2021-05-05 2025-04-10 Hoffmann La Roche Process for preparing btk inhibitors
CN113603685A (zh) * 2021-07-23 2021-11-05 都创(上海)医药开发有限公司 Fenebrutinib化合物的晶型及其制备方法和用途
JP2024542984A (ja) 2021-10-26 2024-11-19 ニューリックス セラピューティクス，インコーポレイテッド がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
WO2023137225A1 (en) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Btk degrader
TW202346276A (zh) 2022-01-27 2023-12-01 日商田邊三菱製藥股份有限公司 新穎之ｂ０ａｔ１抑制劑
EP4471012A1 (en) * 2022-01-28 2024-12-04 HUTCHMED Limited Synthesis method for 7,8-dihydro-2h-cyclopentapyrrolopyrazinone compound
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
AR132314A1 (es) 2023-04-06 2025-06-11 Mitsubishi Tanabe Pharma Corp Nuevo inhibidor de b0at1
CN121194782A (zh) 2023-05-16 2025-12-23 基因泰克公司 使用布鲁顿酪氨酸激酶抑制剂来治疗复发型多发性硬化症的方法
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2025031344A1 (zh) * 2023-08-07 2025-02-13 广州麓鹏制药有限公司 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
JP4463548B2 (ja) 2001-07-12 2010-05-19 リアクサ・リミテッド マイクロカプセル化触媒、及びその製造法と使用法
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
EP2457895A1 (en) 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
NZ555681A (en) 2004-11-10 2009-08-28 Cgi Pharmaceuticals Inc Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
WO2006099075A2 (en) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
ATE504565T1 (de) 2005-10-07 2011-04-15 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es) 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR063706A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
DK2529622T3 (en) * 2006-09-22 2018-05-07 Pharmacyclics Llc INHIBITORS OF BRUTON-TYROSINKINASE
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
JP5587193B2 (ja) * 2007-10-23 2014-09-10 エフ．ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AU2009211514B2 (en) * 2008-02-05 2014-02-20 F. Hoffmann-La Roche Ag Novel pyridinones and pyridazinones
JP5529852B2 (ja) 2008-05-06 2014-06-25 ジリード コネティカット，インコーポレイティド 置換アミド、その製造法及びＢｔｋインヒビターとしての使用
PH12012502375A1 (en) * 2008-06-24 2013-06-17 Hoffmann La Roche Novel substituted pyridin-2-ones and pyridazin-3-ones
HRP20130698T1 (en) 2008-07-02 2013-10-11 F. Hoffmann - La Roche Ag Novel phenylpyrazinones as kinase inhibitors
CA2636807A1 (en) 2008-07-04 2010-01-04 Steven Splinter Methods for obtaining cyclopamine
CA2726460C (en) 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
JP5497152B2 (ja) * 2009-04-24 2014-05-21 エフ．ホフマン−ラ ロシュ アーゲー ブルトン型チロシンキナーゼの阻害薬
US8765754B2 (en) * 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US8785440B2 (en) * 2009-09-04 2014-07-22 Biogen Idec Ma, Inc. Bruton's tyrosine kinase inhibitors
WO2011140488A1 (en) * 2010-05-07 2011-11-10 Gilead Connecticut, Inc. Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
CN103189369B (zh) 2010-09-01 2016-08-24 吉利德康涅狄格有限公司 吡啶酮/吡嗪酮、其制备方法及使用方法
CA2809662C (en) 2010-09-01 2019-04-16 Gilead Connecticut, Inc. Pyridazinones, method of making, and method of use thereof
WO2012156334A1 (en) 2011-05-17 2012-11-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
MX349372B (es) * 2011-08-17 2017-07-26 Hoffmann La Roche Inhibidores de la tirosina-cinasa de bruton.
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
CA2853967A1 (en) * 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity
MX2014005289A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de piperazina alquilados.
RU2016101548A (ru) * 2013-07-03 2017-08-08 Ф. Хоффманн-Ля Рош Аг Соединения амидов гетероарилпиридона и азапиридона
CN105793251B (zh) * 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
KR102451106B1 (ko) * 2016-02-29 2022-10-06 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물

Also Published As

Publication number Publication date
AR117501A2 (es) 2021-08-11
AU2019216728B2 (en) 2020-04-09
KR20140096097A (ko) 2014-08-04
US20130116235A1 (en) 2013-05-09
JP6571215B2 (ja) 2019-09-04
TWI701250B (zh) 2020-08-11
CO6950472A2 (es) 2014-05-20
TW201741315A (zh) 2017-12-01
CR20140194A (es) 2014-06-03
SG11201401992YA (en) 2014-05-29
TWI652270B (zh) 2019-03-01
CN107011348B (zh) 2020-01-10
CA2853975A1 (en) 2013-05-10
US20240270747A1 (en) 2024-08-15
JP2014532762A (ja) 2014-12-08
ES2898938T3 (es) 2022-03-09
US20140194408A1 (en) 2014-07-10
CL2014001103A1 (es) 2014-10-03
PL3002284T3 (pl) 2019-11-29
UA111756C2 (uk) 2016-06-10
TW202124384A (zh) 2021-07-01
AR088641A1 (es) 2014-06-25
IL232060A (en) 2016-02-29
HRP20191307T1 (hr) 2019-10-18
US8921353B2 (en) 2014-12-30
JP2018080193A (ja) 2018-05-24
US20230279012A1 (en) 2023-09-07
CN104125959B (zh) 2017-05-03
EP4050012A1 (en) 2022-08-31
DK3002284T3 (da) 2019-07-29
IN2014CN03250A (OSRAM) 2015-07-03
NZ624021A (en) 2016-09-30
USRE48239E1 (en) 2020-10-06
EP2773638B1 (en) 2015-10-07
EA023263B1 (ru) 2016-05-31
AU2012332365B2 (en) 2016-09-15
BR112014010459A2 (pt) 2017-04-18
SI2773638T1 (sl) 2015-12-31
TW201326175A (zh) 2013-07-01
US20140378432A1 (en) 2014-12-25
AU2018201557B2 (en) 2019-09-19
PH12014500936A1 (en) 2014-06-09
WO2013067274A1 (en) 2013-05-10
AU2018201557A1 (en) 2018-03-22
EP2773638A1 (en) 2014-09-10
HUE044959T2 (hu) 2019-12-30
SI3002284T1 (sl) 2019-08-30
US8716274B2 (en) 2014-05-06
LT3002284T (lt) 2019-08-12
AU2016273930B2 (en) 2018-03-08
ES2738329T3 (es) 2020-01-22
HUE028019T2 (en) 2016-11-28
US20160228432A1 (en) 2016-08-11
TW201906845A (zh) 2019-02-16
AU2012332365A1 (en) 2014-05-01
EP3521288A1 (en) 2019-08-07
EP3521288B1 (en) 2021-09-08
AU2020202707B2 (en) 2021-09-02
EP4019508A1 (en) 2022-06-29
MA35819B1 (fr) 2014-12-01
AU2016273930A1 (en) 2017-01-12
PT3002284T (pt) 2019-07-17
RS54505B1 (sr) 2016-06-30
CN104125959A (zh) 2014-10-29
US9782405B2 (en) 2017-10-10
EP3002284A1 (en) 2016-04-06
US9238655B2 (en) 2016-01-19
PT2773638E (pt) 2016-01-12
JP5976827B2 (ja) 2016-08-24
US20200062769A1 (en) 2020-02-27
PL3521288T3 (pl) 2021-12-27
HK1201265A1 (en) 2015-08-28
CN107011348A (zh) 2017-08-04
DK2773638T3 (en) 2015-10-19
TR201909849T4 (tr) 2019-07-22
KR20160003328A (ko) 2016-01-08
CA2853975C (en) 2020-02-25
TWI609868B (zh) 2018-01-01
EA201490858A1 (ru) 2014-08-29
PE20141586A1 (es) 2014-10-25
CY1117097T1 (el) 2017-04-05
AU2020202707A1 (en) 2020-05-14
HRP20151442T1 (hr) 2016-01-29
IL232060A0 (en) 2014-05-28
JP2019108342A (ja) 2019-07-04
US10045983B2 (en) 2018-08-14
JP2020183397A (ja) 2020-11-12
PL2773638T3 (pl) 2016-03-31
AU2019216728A1 (en) 2019-09-05
US20190194203A1 (en) 2019-06-27
US20180071286A1 (en) 2018-03-15
ES2555168T3 (es) 2015-12-29
KR101659193B1 (ko) 2016-09-22
ZA201804727B (en) 2023-03-29
MX361807B (es) 2018-12-17
EP3002284B1 (en) 2019-05-22
JP2016028046A (ja) 2016-02-25
US20210079002A1 (en) 2021-03-18
RS59016B1 (sr) 2019-08-30

Similar Documents

Publication Publication Date Title
PH12014500936A1 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
MY160349A (en) Pyridone and aza-pyridone compounds and methods of use
PH12014500966A1 (en) Alkylated piperazine compounds as inhibitors of btk activity
MX2014005285A (es) Compuestos biciclicos de piperazina.
MX2015018038A (es) Compuestos de heteroaril-piridona y aza-piridona-amida.
MX2016007171A (es) Compuestos de heteroaril piridona y azapiridona con funcionalidad electrofila.
MX2014014828A (es) Compuestos de 5-azaindazol y metodos de uso.
MX340013B (es) Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso.
MX2014001239A (es) Compuestos de pirazolo [3,4-c] piridina y metodos de uso.
PH12015500488A1 (en) Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EA201290957A1 (ru) Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
BR112013020329A2 (pt) compostos heterocíclicos como inibidores da pi3-quinase
EA201390879A1 (ru) Трициклические ингибиторы pi3k и способы их применения
PH12013501779B1 (en) Pyrrolopyridines as kinase inhibitors
MX2011012520A (es) Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
SG178899A1 (en) Raf inhibitor compounds and methods of use thereof
PH12015500719A1 (en) Gdf-8-inhibitors
UA116774C2 (uk) Інгібітори серин/треонінкінази
IN2015DN01119A (OSRAM)
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
MX2013012977A (es) Derivados de tiazol.
MX363551B (es) Compuestos derivados de pirazina como inhibidores de cinasa.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
MX2016012007A (es) Compuestos de oxepan-2-il-pirazol-4-il-heterociclil-carboxamida y metodos de uso.

Legal Events

Date Code Title Description
FG Grant or registration